Andreas Halvorsen’s Viking Global Investors said Wednesday it had invested in one of biotechs hottest companies and in the process two of the companies it is involved in.
Roivant Sciences, a company dedicated to promoting forgotten or waylaid drugs, disclosed Halvorse’s financial backing in an announcement that MIT Professor Andrew Lo, Ph.D., would join the board as an independent director. The appointment follows the closing of Roivant’s financing led by Viking Global Investors, the release said.
